23,000 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Bought by Avantax Planning Partners Inc.

Avantax Planning Partners Inc. acquired a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 23,000 shares of the biotechnology company’s stock, valued at approximately $170,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IOVA. AlphaQuest LLC raised its holdings in Iovance Biotherapeutics by 63.6% during the fourth quarter. AlphaQuest LLC now owns 4,613 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 1,794 shares during the last quarter. SBI Securities Co. Ltd. acquired a new position in Iovance Biotherapeutics during the fourth quarter worth $36,000. Impact Partnership Wealth LLC acquired a new position in shares of Iovance Biotherapeutics in the fourth quarter worth $83,000. Clear Creek Financial Management LLC acquired a new position in shares of Iovance Biotherapeutics in the fourth quarter worth $91,000. Finally, KBC Group NV raised its holdings in shares of Iovance Biotherapeutics by 105.7% in the fourth quarter. KBC Group NV now owns 12,303 shares of the biotechnology company’s stock worth $91,000 after acquiring an additional 6,321 shares during the last quarter. 77.03% of the stock is owned by institutional investors and hedge funds.

Iovance Biotherapeutics Trading Down 2.1 %

Iovance Biotherapeutics stock opened at $3.82 on Thursday. The firm has a market capitalization of $1.25 billion, a P/E ratio of -2.56 and a beta of 0.93. The stock has a fifty day moving average price of $5.71 and a 200 day moving average price of $8.19. Iovance Biotherapeutics, Inc. has a 52 week low of $3.58 and a 52 week high of $15.90.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.26). Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. The firm had revenue of $73.69 million during the quarter, compared to the consensus estimate of $72.17 million. As a group, equities analysts predict that Iovance Biotherapeutics, Inc. will post -1.24 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on IOVA. HC Wainwright reissued a “buy” rating and issued a $32.00 price target on shares of Iovance Biotherapeutics in a report on Friday, February 28th. Robert W. Baird cut their price target on Iovance Biotherapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Friday, February 28th. The Goldman Sachs Group cut their price target on Iovance Biotherapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a report on Monday, March 3rd. Chardan Capital cut their price target on Iovance Biotherapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a report on Monday, March 3rd. Finally, Truist Financial cut their price target on Iovance Biotherapeutics from $25.00 to $15.00 and set a “buy” rating for the company in a report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $20.25.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.